Replies to post #580485 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

HyGro,

Thanks for the reply. You need better sources for your research. The DCVax-L cell-based platform technology is supported by clinical data that indicate a high level of safety and efficacy. The interim PD1 data from an additional trial are astonishing too.

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/








https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

[Dr Bala]

Since you studied about the low-grade glioma, please post more on the IDH-mutant type. It would be interesting to know more about the competition. Thanks so much, HyGro.